{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:12:21Z","timestamp":1789665141600,"version":"4.0.1"},"reference-count":91,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Vasc Med"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>\n                    Marfan syndrome (MFS) is a genetic disorder caused by mutations in the\n                    <jats:italic toggle=\"yes\">FBN1<\/jats:italic>\n                    gene, which encodes fibrillin-1, a crucial protein involved in the structure of elastic fibers and the regulation of transforming growth factor-beta (TGF-\u03b2) bioavailability. Defective fibrillin-1 disrupts these fibers, leading to skeletal, ocular, and cardiovascular abnormalities. A key pathological mechanism in MFS is excessive TGF-\u03b2 signaling, which has been targeted by angiotensin receptor blocker (ARB) therapies such as losartan, demonstrating potential in restoring normal phenotypes in experimental models. The aim of this narrative review was to highlight findings that demonstrate the potential of ARBs for MFS. Aortic root dilation is a defining feature of MFS. Studies have shown that losartan therapy significantly reduces the dimensions of the aortic root and sinotubular junction in children. However, its long-term efficacy remains uncertain. Beyond its primary effects on the aorta, chronic losartan treatment enhances endothelial function by promoting nitric oxide-mediated vasodilation, which may help prevent aortic root widening. The drug\u2019s effects are partly attributed to its metabolites, EXP3174 (an angiotensin II type 1 receptor [AT1] antagonist) and EXP3179 (an NADPH oxidase inhibitor). Overexpression of NADPH oxidase in MFS contributes to vascular dysfunction, and EXP3179 mitigates aortic vasoconstriction. Given these mechanisms, ongoing research explores the potential of AT1 receptor antagonists as therapeutic agents in MFS, aiming to improve vascular health and long-term patient outcomes.\n                  <\/jats:p>","DOI":"10.1177\/1358863x251406525","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T11:38:28Z","timestamp":1770118708000},"page":"219-231","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["What\u2019s new about angiotensin receptor blocker (ARB) therapy for Marfan syndrome: A narrative review"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2999-0300","authenticated-orcid":false,"given":"Gustavo","family":"Maciel Oliveira","sequence":"first","affiliation":[{"name":"Department of Anatomy Descriptive and Topographic, Faculty of Santa Marcelina, S\u00e3o Paulo, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2094-9703","authenticated-orcid":false,"given":"Juliana","family":"Junqueira Franco Stoppe","sequence":"additional","affiliation":[{"name":"Department of Anatomy Descriptive and Topographic, Faculty of Santa Marcelina, S\u00e3o Paulo, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3422-1019","authenticated-orcid":false,"given":"Sara Maria","family":"Duarte de Andrade","sequence":"additional","affiliation":[{"name":"Department of Anatomy Descriptive and Topographic, Faculty of Santa Marcelina, S\u00e3o Paulo, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7068-3906","authenticated-orcid":false,"given":"Rodrigo Barbosa","family":"de Souza","sequence":"additional","affiliation":[{"name":"Department of Anatomy Descriptive and Topographic, Faculty of Santa Marcelina, S\u00e3o Paulo, SP, Brazil"},{"name":"Department of Genetics and Evolutionary Biology, University of S\u00e3o Paulo, S\u00e3o Paulo, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1517\/21678707.2014.950223"},{"key":"e_1_3_2_3_2","first-page":"1","article-title":"Critical analysis of aortic dysmorphism in Marfan Syndrome","volume":"34","author":"Souza RB","year":"2017","unstructured":"Souza RB, Cassiano LL, Liberatore AMA, et al. Critical analysis of aortic dysmorphism in Marfan Syndrome. J Morphol Sci 2017; 34: 1\u20136.","journal-title":"J Morphol Sci"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-018-0399-4"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00298-7"},{"key":"e_1_3_2_6_2","first-page":"1993","volume-title":"GeneReviews\u00ae","author":"Dietz H","unstructured":"Dietz H. FBN1-related Marfan syndrome. In: Adam MP, Feldman J, Mirzaa GM et al. (eds) GeneReviews\u00ae [Internet]. University of Washington, Seattle, 1993\u20132025."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2015.05.002"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1302285"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1116"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1124287"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.6.789"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960270315"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13772-3"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.niox.2022.12.002"},{"key":"e_1_3_2_15_2","first-page":"220","article-title":"A case of congenital deformity of the four limbs, more pronounced at the extremities, characterized by lengthening of the bones with a certain degree of thinning","volume":"13","author":"Marfan BJA","year":"1896","unstructured":"Marfan BJA. [A case of congenital deformity of the four limbs, more pronounced at the extremities, characterized by lengthening of the bones with a certain degree of thinning] [Article in French]. Bull Mem Med Society Hospitals Paris. 1896; 13: 220\u2013226.","journal-title":"Bull Mem Med Society Hospitals Paris"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0888-7543(91)90264-F"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/14779072.2019.1704625"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-80614-9_8"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.103.6.2499"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.115.14.2817"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2013.9"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/genetics\/iyad189"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-09665-w"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20166615"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M209256200"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2006.12.006"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1192152"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1192149"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.66004.x"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000182521.44440.c5"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0b013e3283232a45"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-11-3"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2010.04.008"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2011.02.009"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2010.12.070"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.02.019"},{"key":"e_1_3_2_37_2","volume-title":"Marfan syndrome","author":"Salik I","year":"2023","unstructured":"Salik I, Rawla P. Marfan syndrome. In: StatPearls [Internet]. StatPearls Publishing, 2023."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262826"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.07.004"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.21037\/acs.2017.11.10"},{"key":"e_1_3_2_41_2","first-page":"8218","article-title":"Marfan syndrome and aortic involvement: A narrative review","volume":"27","author":"Carbone RG","year":"2023","unstructured":"Carbone RG, Monselise A, Puppo F. Marfan syndrome and aortic involvement: A narrative review. Eur Rev Med Pharmacol Sci 2023; 27: 8218\u20138224.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.11.082"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001106"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706585"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.06.019"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2013-304946"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-018-1916-6"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2018.01.016"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.03.064"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-021-02761-4"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz746.0154"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01534-3"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32518-8"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv151"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv575"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1080\/00015385.2017.1314134"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199405123301902"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(94)90762-5"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht334"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.114.000950"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa377"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404731"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.07.052"},{"key":"e_1_3_2_64_2","first-page":"371","article-title":"COMPARE and Pediatric Heart Network Investigator trials: Losartan finally validated in humans with Marfan, but much work remains!","volume":"2014","author":"Yacoub M","year":"2014","unstructured":"Yacoub M, Radford M. COMPARE and Pediatric Heart Network Investigator trials: Losartan finally validated in humans with Marfan, but much work remains! Glob Cardiol Sci Pract 2014; 2014: 371\u2013378.","journal-title":"Glob Cardiol Sci Pract"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-019-00149-3"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.04.186"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.04.034"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X15569868"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1177\/2047487319861231"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2019.03.018"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2023.02.003"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-022-02976-z"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3723"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.122.317381"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.122.318448"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.058173"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544080-00003"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11070617"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.129353"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00770.2015"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2018.02.023"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14587"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2022.11.001"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2022.107112"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176663"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2017.11.006"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.509760"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.03.051"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2009.01178.x"},{"key":"e_1_3_2_90_2","first-page":"41","article-title":"Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: Comparison with other angiotensin II type 1 receptor blockers","volume":"25","author":"Kakuta H","year":"2005","unstructured":"Kakuta H, Sudoh K, Sasamata M, Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: Comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25: 41\u201346.","journal-title":"Int J Clin Pharmacol Res"},{"key":"e_1_3_2_91_2","volume-title":"StatPearls","author":"Mulla S","year":"2024","unstructured":"Mulla S, Patel P, Siddiqui WJ. Losartan. In: StatPearls [Internet]. StatPearls Publishing, 2024."},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2019.1176"}],"container-title":["Vascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1358863X251406525","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1358863X251406525","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1358863X251406525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:36:40Z","timestamp":1777693000000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1358863X251406525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/1358863X251406525"],"URL":"https:\/\/doi.org\/10.1177\/1358863x251406525","relation":{},"ISSN":["1358-863X","1477-0377"],"issn-type":[{"value":"1358-863X","type":"print"},{"value":"1477-0377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]}}}